欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Clevudine_163252-36-6_产品详情
163252-36-6
  • names:

    Clevudine

  • CAS号:

    163252-36-6

    MDL Number:
  • MF(分子式): C10H13FN2O5 MW(分子量): 260.22
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Clevudine
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM000536-50mg 50mg 99.95% ¥ 9166.50 ¥ 9166.50 2-3天
- +
¥ 0.00
YZM000536-10mg 10mg 99.95% ¥ 2912.00 ¥ 2912.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 163252-36-6
Inchi
InchiKey
分子式 Formula C10H13FN2O5
分子量 Molecular Weight 260.22
溶解度Solubility 生物体外In Vitro:DMSO溶解度≥ 50 mg/mL(192.15 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月
Clevudine(CAS:163252-36-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Clevudine is an antiviral drug for the treatment of hepatitis B.
IntroductionClevudine is an antiviral drug for the treatment of hepatitis B.
Application1
Application2
Application3
Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBV Clevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Lee, H.S., et al., A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2006. 43(5): p. 982-8.
【2】.Jang, J.H., et al., Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat, 2011. 18(2): p. 84-90.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents